Table 1.
Characteristics of patients with a BAL BDG test for evaluation of fungal pneumonia
| Category | Demographic or Clinical Feature | N (%) |
|---|---|---|
| Gender | Male | 72 (54.5) |
| Female | 60 (45.5) | |
| Race | Caucasian | 73 (55.3) |
| Black / African-American | 28 (16.2) | |
| Hispanic | 19 (l4.4) | |
| Other or unknown | 12 (9.l) | |
| aUnderlying Disease or Risk Factor for IFI | Hematologic malignancy | 58 (43.9) |
| Allogeneic stem cell transplantation | 40 (30.3) | |
| bNeutropenia (absolute neutrophil count < 500 / mm3) | 31 (23.5) | |
| Steroids (> 0.3 mg / kg / d prednisone equivalent) Graft versus host disease (acute or chronic) |
30 (22.7) 25 (18.9) |
|
| Severe Aplastic Anemia (SAA) | 17 (l2.9) | |
| Human Immunodeficiency Virus (HIV) | 14 (10.6) | |
| Chronic Granulomatous Disease (CGD) | 6 (4.5) | |
| Concomitant medications | cSystemic antibiotic(s) within one week of BAL | 112 (84.8) |
| dSystemic antifungal(s) at time of diagnosis | 78 (59.1) | |
| Azoles | Fluconazole | 37 (28.0) |
| Voriconazole | 33 (25.0) | |
| Posaconazole | 9 (6.8) | |
| Echinocandins | Caspofungin | 14 (10.6) |
| Micafungin | 12 (9.1) | |
| Anindulafungin | 7 (5.3) | |
| Polyenes | Liposomal amphotericin | 14 (10.6) |
a
Patients often had more than one underlying disease or risk factor
b
Average duration of neutropenia prior to diagnosis was 45 days
c
Antibacterial agent(s); patients often received multiple antibacterial drugs
d
Antifungal agent(s) within 3 months prior to diagnosis; some patients received more than one antifungal agent